PULMOCEF

This brand name is authorized in Nigeria.

Active ingredients

The drug PULMOCEF contains one active pharmaceutical ingredient (API):

1	Cefuroxime UNII Z49QDT0J8Z - CEFUROXIME AXETIL
	Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
	Read more about Cefuroxime

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-1970	Tablet	Pulmocef 250 Tablets TAB 250 mg	Each tablet contains: Cefuroxime Axetil USP equiv. to Cefuroxime 250 mg	09/02/2021
A4-1971	Tablet	Pulmocef 500 Tablets TAB 500 mg	Film-coated tablet Each tablet contains: Cefuroxime Axetil USP equiv. to Cefuroxime 500 mg	09/02/2021
B4-4327	Powder for suspension	PULMOCEF POWDER FOR ORAL SUSPENSION PWD_F_SOL 125 mg/5 mL 1X100ML	67 RNW-PP-304724 PULMOCEF POWDER FOR ORAL SUSPENSION CEFUROXIME AXETIL 125MG/5ML CEFUROXIME AXETIL USP EQUIVALENT TO CEFUROXIME 125MG EXCIPIENTS Q.S B4-4327 Drugs Imported Products 1X100ML Prescription Only Medicine (POM) 1/25/2023 GENEITH PHARMACEUTICALS LIMITED, ADEWALE CRESCENT, OFF EWENLA STREET, OSHODI ISOLO LAGOS 8122912281 ngouzoamaka@yahoo.com ZIM LABORATORIES LTD., ZIM LABORATORIES LTD., B-21/22 MIDC, AREA, KALMESHWAR, NAGPUR - 441 501, INDIA, India	27/07/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01DC02	Cefuroxime	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01D Other beta-lactam antibacterials → J01DC Second-generation cephalosporins
Discover more medicines within J01DC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-1970, A4-1971, B4-4327